Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Osteosarcoma 1Neoplasm Metastasis 1Adenoma, Islet Cell 1

Interventions

Cyclophosphamide 8fludarabine 6cabozantinib 5Temozolomide 4Doxorubicin 4Zoledronic Acid 3X-Rays 3Vincristine 3Methotrexate 3Ifosfamide 3Gemcitabine 3Cisplatin 3irinotecan sucrosofate 2atezolizumab 2Surgical Procedures, Operative 2Sunitinib 2Specimen Handling 2Radiosurgery 2Phantoms, Imaging 2Mesna 2Magnetic Resonance Spectroscopy 2Irinotecan 2Eflornithine 2Disulfiram 2Biopsy 2vactosertib 1trilaciclib 1trametinib 1talazoparib 1surufatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Osteosarcoma × Gefitinib × Clear all
NCT07477457 2026-03-17

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
45 enrolled
Sarcoma

Neoplasm Metastasis, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡